Thyrocare Technologies (NSE:THYROCARE) Long-Term Debt: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:THYROCARE Thyrocare Technologies Ltd NSE:THYROCARE
82 GF Score
Price ₹603.25
GF Value ₹419.69
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Thyrocare Technologies Long-Term Debt?

Thyrocare Technologies NSE:THYROCARE +0.87% 82 Long-Term Debt is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:THYROCARE with a GF Score™ of 82/100 and a GF Value™ of ₹419.69 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Thyrocare Technologies's Long-Term Debt for the quarter that ended in Jun. 2026 was ₹0 Mil.

Thyrocare Technologies's annual Long-Term Debt declined from Mar. 2024 (₹109 Mil) to Mar. 2025 (₹0 Mil) but then stayed the same from Mar. 2025 (₹0 Mil) to Mar. 2026 (₹0 Mil).

Thyrocare Technologies  (NSE:THYROCARE) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Thyrocare Technologies Long-Term Debt Related Terms

Thyrocare Technologies Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Thyrocare Technologies's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Thyrocare Technologies Long-Term Debt Chart

Thyrocare Technologies Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 109.10 0.00 0.00

Thyrocare Technologies Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:THYROCARE
82GF Score
Thyrocare Technologies Ltd NSE:THYROCARE
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of ₹0 Mil mean?
Thyrocare Technologies (NSE:THYROCARE) has a Long-Term Debt of ₹0 Mil as of Jun. 2026.
Is Thyrocare Technologies' Long-Term Debt too high?
Thyrocare Technologies' current Long-Term Debt is ₹0 Mil. Overall, Thyrocare Technologies has a GF Score™ of 82/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Thyrocare Technologies' Long-Term Debt compare to TMO and DHR?
Thyrocare Technologies' Long-Term Debt of ₹0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Diagnostics & Research company?
A good Long-Term Debt depends on the Medical Diagnostics & Research industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Thyrocare Technologies's current Long-Term Debt is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thyrocare Technologies stock overvalued right now?
Based on GuruFocus' analysis, Thyrocare Technologies (NSE:THYROCARE) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹419.69, compared to a current price of ₹603.25 — trading 43.7% above its estimated fair value. The current Long-Term Debt is ₹0 Mil. Thyrocare Technologies' overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Thyrocare Technologies (NSE:THYROCARE), the current Long-Term Debt is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Thyrocare Technologies (NSE:THYROCARE) Overvalued in 2026?

Based on GuruFocus' analysis, Thyrocare Technologies stock appears to be overvalued. The current stock price of ₹603.25 is trading 43.7% above its estimated GF Value™ of ₹419.69. GuruFocus considers Thyrocare Technologies to be Significantly Overvalued.

Key valuation signals for NSE:THYROCARE:

  • Long-Term Debt: ₹0 Mil
  • GF Value™: ₹419.69 vs. price of ₹603.25 (43.7% above fair value)
  • GF Score™: 82/100 with 5 warning signs

No single metric tells the full story. See the NSE:THYROCARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Thyrocare Technologies Business Description

Other Exchanges 539871:India
Address D-37/3, TTC Industrial Area, MIDC, Turbhe, Opposite Sandoz, Navi Mumbai, MH, IND, 400703
Thyrocare Technologies Ltd is a diagnostics & research company. The company has three business segments: Diagnostic Testing Services, Imaging Services, and Others: Sale of testing equipment and consumables. The Diagnostic Testing Services segment provides Diagnostic and testing services, selling of consumables used for the collection and promotion of the pathology segment. The company majorly earns the majority of its revenue from the Diagnostic Testing Services segment. The Imaging Services segment operates Diagnostic and imaging services, selling of radio-pharmaceuticals, and selling of consumables for reporting. The Other business segment is engaged in the selling of glucometers and glucostrips under the brand name Sugarscan. The company earns the vast majority of its revenue in India.
82GF Score

Get the complete analysis for NSE:THYROCARE

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹603.25
Price
₹419.69
GF Value